- Technical Note
- Open Access
Optimizing the process of nucleofection for professional antigen presenting cells
BMC Research Notes volume 8, Article number: 472 (2015)
In times of rapidly increasing numbers of immunological approaches entering the clinics, antigen delivery becomes a pivotal process. The genuine way of rendering antigen presenting cells (APC) antigen specific, largely influences the outcome of the immune response. Short peptides bear the demerit of HLA restriction, whereas the proper way of delivery for long peptide sequences is currently a matter of debate. Electroporation is a reliable method for antigen delivery, especially using nucleic acids. The nucleofection process is based on this approach with the twist of further ensuring delivery also into the nucleus. Beside the form of antigen, the type of APC used for immune response induction may be crucial. Dendritic cells (DC) are by far the most commonly used APC; however B cells have entered this field as well and have gained wide acceptance.
In this study, we compared B cells to DC with regard to nucleofection efficiency and intensity of resulting antigen expression. APC were transfected either with plasmid DNA containing the reporter gene green fluorescent protein (GFP) or directly with in vitro-transcribed (IVT) GPF mRNA as a surrogate antigen. Out of nearly 100 different nucleofection programs tested, the top five for each cell type were identified and validated using cells from cancer patients. Flow cytometric analyses of transfected cells determining GFP expression and viability revealed a reverse correlation of efficiency and viability. Finally, donor dependant variances were analyzed.
In summary, nucleofection of both DC and B cells is feasible with plasmid DNA and IVT mRNA. And no differences with regard to nucleofectability were observed between the two cell types. Using IVT mRNA omits the danger of genomic integration and plasmid DNA constructs permit a more potent and longer lasting antigen expression.
The proper presentation of antigens is a crucial step in the orchestration of immune responses. In this context, antigen presenting cells (APC) take up antigens, process them and present epitopes in the respective major histocompatibility complex (MHC) molecules . Generally, two cell types are recognized as so called professional APC: the more prominent representatives are dendritic cells (DC) frequently utilized in all sorts of cellular immunotherapies [2, 3]. However, B cells have also gained wide acceptance as APC [4–7]. Different methodologies have been successfully developed to render these antigen presenters most potently antigen-specific. The simplest approach is to exogenously load peptides onto the MHC molecules. Major drawbacks hereby are restriction to selected MHC molecules and lack of (endogenous) antigen procession [8, 9]. More refined approaches use nucleic acids as source of antigen. With regard to the nucleic acids, DNA is easier to handle than RNA: cloning DNA sequences into respective eukaryotic expression vectors is longstanding routine, and manipulation of cells by viral transduction is commonly performed [10–13]. DNA can be easily amplified by PCR approaches and, as opposed to the peptide synthesis, allows simple and fast testing and optimization of responses to different antigens also in preclinical research laboratories. Since nucleic acids can easily be designed to be recognized by the cellular protein synthesis machinery, they will subsequently be properly translated into long peptides or proteins . Then, the latter will also be substrates of the endogenous antigen processing machinery, resulting in efficient presentation on the cells’ MHC repertoire, thus overcoming the MHC restriction issue . On the downside, manipulation with DNA may lead to stable integration and potentially transgenic cells are a red flag for subsequent clinical applications . RNA may be synthesized from in vitro transcription (IVT) constructs, and so far, no risk of genomic integration has been recognized ; au contraire it is considered safe for clinical approaches . In this line of argumentation, the method applied for APC transformation is of importance. Viral transductions bear the risk of stably creating transgenic cells [19, 20]. Thus, non-viral delivery methods are of great interest. Nucleofection is such a technique; by combining standard electroporation with special carrier and buffer solutions, it ensures direct nuclear delivery of the constructs .
In this study, we wanted to compare the two major APC types and test nucleofectability using plasmid DNA and IVT mRNA samples. The goal was to optimize the nucleofection process using cells of healthy volunteers and validating the results with—clinically relevant—patient-derived cells.
Results and discussion
Non-viral delivery of nucleic acids to APC is necessary in many clinical settings; especially in the context of cellular immunotherapies. We optimized the process of nucleofection, a method—which is applicable both for plasmid DNA and IVT mRNA.
Nucleofection of DC
In a first step, we assessed the differentiation stage at which nucleofection of monocyte derived DC would best be applied. Therefore, we analyzed the nucleofection efficacy—as measured by green fluorescent protein (GFP) positive cells post nucleofection with pmaxGFP plasmid—in monocytes, immature and mature DC (Fig. 1). Nucleofection was most efficient in immature DC with all three programs tested (U-022, V-001 and X001) and viability tended to be highest in immature DC as well (Fig. 1; Additional file 1: Figure S1). In a next step, nucleofection of immature DC with 98 different programs was performed to determine optimal settings (see Additional file 2: Table S1 for a detailed list). The percentage of vital GFP positive cells with the top ten programs ranged from 30 % (±4) to 45 % (±8) with a mean viability rate of 51 % (Fig. 2).
Nucleofection of B cells (plasmid DNA)
B cells have gained acceptance as APC, so we wanted to compare their nucleofectability to that of DC. A total of 81 programs (see Additional file 2: Table S1, Additional file 3: Table S2 for a detailed list of B cell lines and programs) was tested on an EBV immortalized B cell line (Bc ML) and the ten most effective programs were then verified using two further B cell lines (Bc WR and Bc 736). Nucleofection efficacy was comparable to that achieved with DC; it ranged from 32 % (±15) to 43 % (±7) with a mean viability rate of 53 % (Fig. 3). Since we aimed at transferring the process to patient derived B cell lines, the top five programs were selected taking nucleofection efficiency and viability into account and subsequently tested further on three patient derived B cell lines. Here, the efficacy ranged from 38 % (±19) to 52 % (±19) with a mean viability of 32 % (Fig. 4).
Nucleofection of B cells (IVT mRNA)
The risk of stable integration into the host genome makes DNA less favorable with regard to clinical approaches. The nucleofection of B cells using IVT mRNA was thus investigated next. Therefore, two patient derived B cell lines were analyzed using the top five programs as determined with plasmid DNA. The efficacy ranged from 38 % (±27) to 48 % (±25) with a mean viability of 34 % (Fig. 5). Contrary to what is described in literature  and thus to some extend surprising, the efficacy was not higher for IVT mRNA compared to plasmid DNA. We thus performed a time kinetics analysis; assessing the percentage of vital GFP positive cells 4, 8, and 20 h post nucleofection (Fig. 6). GFP expression was well detectable already 4 h after nucleofection, peaked at 8 h and started decreasing thereafter but was still detectable 20 h post nucleofection (Fig. 6). Even longer expression periods have been described for IVT mRNA-nucleofected GFP of DC [22, 23]. Although (anti)gene transduction efficiency is by far not the only factor determining the overall antigen presentation capacity of APC, enhanced efficiency of (anti)gene delivery is likely to improve antigen processing and presentation resulting in increased levels of induced immune responses (reviewed by Garg and colleagues in ).
We finally assessed the influence of the IVT mRNA amount used on the efficacy of nucleofection. We compared the effects using 3 and 10 µg IVT mRNA in addition to 1 µg plasmid DNA nucleofection (Fig. 7). Here, 10 µg IVT mRNA was most effective.
Comparison of nucleofection with plasmid DNA and IVT mRNA
The amount of nucleic acid necessary for highly successful nucleofection is tenfold higher for IVT mRNA compared to plasmid DNA (Fig. 7). With regard to the intensity of protein expression—as determined by fluorescence intensity in flow cytometry—plasmid DNA is more potent than IVT mRNA (Fig. 8). Yet, for IVT mRNA an increase in efficacy could be achieved by using more RNA (3 vs. 10 µg); this was not the case for plasmid DNA, where rather a decrease in viability was observed (data not shown). Finally, in terms of viability, no great differences were observed between the two types of nucleic acids (Additional file 4: Figure S2, Additional file 5: Figure S3).
Non viral delivery of nucleic acids to APC using the technology termed nucleofection was feasible and successful for both major types of antigen presenters (DC and B cells) coming from healthy donors as well as from tumor patients. Very recently Maeß and colleagues published an optimized process for nucelofecting of macrophages—a further important player in the immune system. More precisely nucleofection was performed on the human macrophage and monocyte cell line THP-1. Although they only present nucleofection of this cell line with one program, the process was analyzed for plasmid DNA and siRNA . A great variance, in especially with regard to efficacy, between different individuals was observed in our analysis (see SD in Figs. 1, 2, 3, 4, 5). However, the individual most efficient program was among the top five programs selected for the respective cell type. Thus, we do not propose one overall best nucleofection program but rather a handful carefully selected programs to choose amongst.
The nucleofectability of DC and B cells were comparable both with regard to efficacy and handling of cells in the process. Since generation of monocyte derived DC is laborious, expensive and purity as well as efficiency of DC generation differs largely between donors, B cells are favorable in this regard. Besides, they can easily be expanded in vitro which DC cannot .
In comparison to B cells from healthy donors, the nucleofection of patient derived B cells was more successful. Yet, the viability was lower. So, the approach is very well applicable in a pathological setting (at least in cancer patients).
Improved transfection efficacy may be achieved, but at the expense of viability. Nevertheless, the nucleofection process should be performed at optimal conditions: minimize time of cells in nucleofection buffer (do not exceed 15 min), pre-heat subsequent culture media (37 °C), prepare material (culture dishes, pipettes, cuvettes) and wash cells out of the cuvette immediately after nucleofection.
Electroporation is an effective (anti)gene transduction method which has in the context of APC not only been proven to allow effective targeting of CD8+ T cells  but also of CD4+ T cells via the MHC class 2 pathway .
Finally, we would like to point out that the manner for handling APC prior to and during nucleofection is crucial. Cell densities should not be too high; we recommend splitting B cells, change media and resuspend the cells the day before nucleofection.
In summary, we here successfully optimized nucleofection of both APC types used in (pre)clinical settings, DC and B cells, for plasmid DNA and IVT mRNA. Subsequent studies profit from our major findings: (1) patient-derived APC are well-suited, (2) due to high individual differences, however, five programs should be tested, (3) DC have to be nucleofected in the immature state, (4) plasmid DNA permits a more potent and longer lasting antigen expression, (5) achievable levels of antigen expression are similar for B cells and DC.
The human colon cancer cell line HROC24, established in our lab , was cultured in DMEM/Ham’s F12 (1:1) and all EBV B cell lines (for detailed list see Additional file 3: Table S2) were cultured in IMDM. DC were generated as described before . Monocytes were isolated by MACS cell separation of peripheral blood mononuclear cells using human CD14 MicroBeads (Miltenyi, Bergisch Gladbach, Germany), incubated in RPMI supplemented with Il-4 (20 ng/ml; Immunotools, Friesoythe, Germany) and GM-CSF (1,000 IU/ml; Immunotools) for 5 days and matured using TNFα (120 ng/ml; Immunotools) and Il-1β (120 ng/ml; Immunotools) for two additional days. All culture media were supplemented with 10 % fetal calf serum (FCS Gold, PAA Cölbe, Germany), 2 mmol/l l-glutamine and 1 % penicillin–streptomycin. Cell cultures were incubated at 37 °C with 5 % CO2. Media and supplements, if not indicated otherwise, were purchased at Pan Biotech (Aidenbach, Germany). Maturation states of the DC were routinely checked as described before .
Nucleofection of plasmid DNA was performed using the pmaxGFP plasmid (Lonza, Basel, Switzerland). For mRNA nucleofection, the GFP gene was cloned from the pCR2.1-EGFP plasmid using EcoRI (Promega, Madison, United States) into the PGEM-3-Z vector (Promega) especially designed for highly efficient IVT. 1 µg NarI (Promega) linearized PGEM-3-Z-GFP plasmid served as template for mRNA synthesis using AmpliScribe T7 Flash, Poly(A) Polymerase Tailing Kit and ScriptCap m7G Capping System reagents by epicentre (Madison, United States) according to the manufacturer’s instructions to produce capped IVT mRNA with a poly(A) tail. All nucleic acid concentration determinations were done using a NanoDrop (Thermo-Scientific, Waltham, United States).
Cells were harvested, washed, and resuspended in solution V (Lonza; i.e. 90 mM Na2HPO4, 90 mM NaH2PO4, 5 mM KCl, 10 mM MgCl2 and 10 mM sodium succinate dissolved in bi-distilled water): DC (1 × 104/µl if not indicated otherwise) or Bc (3 × 104/µl if not indicated otherwise). Subsequently, 100 µl of the cell suspension was mixed with 1 µg plasmid DNA or 10 µg IVT mRNA (if not indicated otherwise), and electroporated in a 0.2 cm cuvette using the Nucleofector™ II device (Lonza). Various nucleofection programs (see Additional file 2: Table S1) were compared in order to assess their effect on transfection efficiency. One million HROC24 cells were nucleofected for each batch IVT mRNA (3 µg) to assure consistent quality.
GFP-transfected cells were checked for GFP expression 20 h (if not indicated otherwise) after nucleofection by flow cytometry. Briefly, cells (5 × 105 cells) were washed once in PBS and resuspended in 200 µl PBS. Propidium iodine at a final concentration of 20 µg/ml was added directly prior to flow cytometric analysis on a FACScalibur analytical flow cytometer (Becton–Dickinson, Heidelberg, Germany) to allow for exclusion of dead cells and thus to simultaneously assess cell viability and GFP positivity. Viability was calculated as follows: 100 % minus % Propidium iodine positive cells.
The efficiency (defined as the percentage viable-GFP positive cells) for each program and cell line was calculated as follows:
antigen presenting cell
green fluorescent protein
major histocompatibility complex
Mantegazza AR, Magalhaes JG, Amigorena S, Marks MS. Presentation of phagocytosed antigens by MHC class I and II. Traffic. 2013;14(2):135–52. doi:10.1111/tra.12026.
Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF. Dendritic cell-based cancer gene therapy. Hum Gene Ther. 2009;20(10):1106–18. doi:10.1089/hum.2009.145.
Yi DH, Appel S. Current status and future perspectives of dendritic cell-based cancer immunotherapy. Scand J Immunol. 2013;78(2):167–71. doi:10.1111/sji.12060.
Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100(11):2757–65.
Van den Bosch GA, Ponsaerts P, Nijs G, Lenjou M, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. Clin Exp Immunol. 2005;139(3):458–67. doi:10.1111/j.1365-2249.2005.02733.x.
Zentz C, Wiesner M, Man S, Frankenberger B, Wollenberg B, Hillemanns P, Zeidler R, Hammerschmidt W, Moosmann A. Activated B cells mediate efficient expansion of rare antigen-specific T cells. Hum Immunol. 2007;68(2):75–85. doi:10.1016/j.humimm.2006.12.004.
Kondo E, Gryschok L, Klein-Gonzalez N, Rademacher S, Weihrauch MR, Liebig T, Shimabukuro-Vornhagen A, Kochanek M, Draube A, von Bergwelt-Baildon MS. CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol. 2009;155(2):249–56. doi:10.1111/j.1365-2249.2008.03820.x.
Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296–306. doi:10.1038/nri1592.
Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195–203. doi:10.1172/JCI31205.
Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 1996;56(24):5672–7.
Szabolcs P, Gallardo HF, Ciocon DH, Sadelain M, Young JW. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood. 1997;90(6):2160–7.
Ponnazhagan S, Mahendra G, Curiel DT, Shaw DR. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol. 2001;75(19):9493–501. doi:10.1128/JVI.75.19.9493-9501.2001.
Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C, van der Bruggen P, Thielemans K. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med. 2003;5(8):654–67. doi:10.1002/jgm.400.
Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest. 2000;106(9):1065–9. doi:10.1172/JCI11405.
Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004;199:251–63. doi:10.1111/j.0105-2896.2004.00139.x.
Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci. 1995;772:30–9.
Tavernier G, Andries O, Demeester J, Sanders NN, De Smedt SC, Rejman J. mRNA as gene therapeutic: how to control protein expression. J Control Release. 2011;150(3):238–47. doi:10.1016/j.jconrel.2010.10.020.
Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol. 2011;23(3):399–406. doi:10.1016/j.coi.2011.03.007.
Gordon EM, Anderson WF. Gene therapy using retroviral vectors. Curr Opin Biotechnol. 1994;5(6):611–6.
Lenz P, Bacot SM, Frazier-Jessen MR, Feldman GM. Nucleoporation of dendritic cells: efficient gene transfer by electroporation into human monocyte-derived dendritic cells. FEBS Lett. 2003;538(1–3):149–54. doi:10.1016/S0014-5793(03)00169-8.
Gresch O, Engel FB, Nesic D, Tran TT, England HM, Hickman ES, Körner I, Gan L, Chen S, Castro-Obregon S, Hammermann R, Wolf J, Müller-Hartmann H, Nix M, Siebenkotten G, Kraus G, Lun K. New non-viral method for gene transfer into primary cells. Methods. 2004;33(2):151–63. doi:10.1016/j.ymeth.2003.11.009.
Landi A, Babiuk LA. van Drunen Littel-van den Hurk S: High transfection efficiency, gene expression, and viability of monocyte-derived human dendritic cells after nonviral gene transfer. J Leukoc Biol. 2007;82(4):849–60. doi:10.1189/jlb.0906561.
Melhem NM, Gleason SM, Liu XD, Barratt-Boyes SM. High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA. Clin Vaccine Immunol. 2008;15(9):1337–44. doi:10.1128/CVI.00154-08.
Garg NK, Dwivedi P, Prabha P, Tyagi RK. RNA pulsed dendritic cells: an approach for cancer immunotherapy. Vaccine. 2013;31(8):1141–56. doi:10.1016/j.vaccine.2012.12.027.
Maeß MB, Wittig B, Lorkowski S. Highly efficient transfection of human THP-1 macrophages by nucleofection. J Vis Exp. 2014;91:e51960. doi:10.3791/51960.
Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, Dilloo D, Heslop HE, Brenner MK, Rooney CM, Leen AM. Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009;17(9):1616–25. doi:10.1038/mt.2009.140.
Van Gulck ER, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, De Roo A, Colebunders R, Van den Bosch G, Van Bockstaele DR, Van Tendeloo VF, Allard S, Verrier B, Marañón C, Hoeffel G, Hosmalin A, Berneman ZN, Vanham G. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood. 2006;107(5):1818–27. doi:10.1182/blood-2005-01-0339.
Maletzki C, Stier S, Gruenert U, Gock M, Ostwald C, Prall F, Linnebacher M. Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PLoS One. 2012;7(12):e52485. doi:10.1371/journal.pone.0052485.
Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol. 2010;99(2):261–72. doi:10.1007/s11060-010-0131-y.
Xu X, Stockhammer F, Schmitt A, Casalegno-Garduno R, Enders A, Mani J, Classen CF, Linnebacher M, Freund M, Schmitt M. Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells. Int J Oncol. 2012;40(3):764–72. doi:10.3892/ijo.2011.1269.
CSM and TW carried out the experimental work and analyzed the results. ML, CFC and EK helped interpret the results. CSM and ML drafted the manuscript. All authors read and approved the final manuscript.
This work was supported by the “Stiftung Tumorforschung Kopf-Hals”.
Compliance with ethical guidelines
Competing interests The authors declare that they have no competing interests.